Back

Interview: C4 Therapeutics targets protein degradation

Feb 02, 2016 Tags: Drug development

Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a way to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a USD 73 million series A financing, and a deal with Roche which has a potential biodollar value north of USD 750 million, C4 Therapeutics co-founder and executive chairman Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.

Interviewee: Marc Cohen – Co-Founder and Executive Chairman, C4 Therapeutics

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights